MK-677 vs Sermorelin: Why the Route Matters

MK-677 vs sermorelin isn't a choice between two versions of the same peptide. MK-677, also called ibutamoren, is an oral non-peptide drug that copies part of the hunger hormone ghrelin's signal. Sermorelin is a 29-amino-acid peptide that copies growth hormone-releasing hormone, the body's message to release growth hormone.

Both can raise growth hormone and the downstream marker IGF-1. But only sermorelin fits the clinician-led, licensed-pharmacy route discussed here. MK-677 has never had an FDA-approved product, and FDA says it cannot lawfully be marketed as a dietary supplement. It should not be treated as a convenient oral substitute for prescribed care.

MK-677 vs sermorelin at a glance

The oral-versus-injection difference is obvious. The more important difference is accountability. A gray-market bottle does not create a prescriber, pharmacy dispensing record or follow-up plan. A prescribed compounded medication does.

Two different doors into the same gland

MK-677 activates the ghrelin receptor, a cell switch that normally responds to the hormone involved in hunger and growth-hormone release. A 2021 structural study showed how ibutamoren binds that receptor as a non-peptide agonist, meaning a non-peptide molecule that turns the receptor on (Liu et al., Nature Communications, 2021).

That also explains why calling MK-677 a SARM is wrong. A SARM acts on the androgen receptor, the docking point for testosterone-like signals. MK-677 does not. Some sellers simply group it with SARMs.

Sermorelin uses the GHRH receptor on the pituitary, the small gland at the base of the brain. The signal prompts a growth-hormone pulse, which may then raise IGF-1, a steadier blood marker that carries many downstream growth signals. Both drugs work upstream of growth hormone. Neither is injected HGH.

What the human studies actually measured

MK-677 has more adult trial data, but more data does not make it an approved or dependable wellness drug. In a 2008 randomized trial, 65 healthy adults ages 60 to 81 received oral MK-677 or placebo. After one year, fat-free mass rose 1.1 kilograms with MK-677 and fell 0.5 kilograms with placebo, but strength and physical function did not improve. Body weight rose 2.7 kilograms versus 0.8 kilograms, fasting glucose rose about 5 mg/dL, and insulin sensitivity fell (Nass et al., Annals of Internal Medicine, 2008). Increased appetite, mild leg swelling and muscle pain were the most frequent side effects.

Sermorelin's adult record is smaller and mixed. In 11 older men treated for six weeks, nightly GHRH(1-29) increased nighttime growth-hormone release but did not change IGF-1, weight, or scanned muscle and fat (Vittone et al., Metabolism, 1997). A separate 16-week study of 19 older adults used a modified GHRH(1-29) analogue and raised IGF-1 within two weeks; lean mass increased only in men (Khorram et al., Journal of Clinical Endocrinology & Metabolism, 1997).

There is no direct MK-677-versus-sermorelin trial. A higher IGF-1 result proves that a pathway moved, not that sleep, recovery, muscle or day-to-day function improved. A provider considering another prescription GH-axis approach may compare sermorelin with CJC-1295, but that is a separate decision with separate evidence.

The MK-677 safety signal is hard to ignore

A later phase 2b trial enrolled 123 older adults recovering from hip fracture. MK-677 raised IGF-1 by 51.4 ng/mL compared with placebo, yet most functional measures did not improve. The study stopped early because of a congestive-heart-failure signal in a limited number of participants (Adunsky et al., Archives of Gerontology and Geriatrics, 2011).

FDA now places ibutamoren mesylate in Category 2 for both 503A and 503B compounding, an interim category for bulk substances the agency says may present significant safety risks. Its current risk summary specifically cites potential heart failure.

This does not make sermorelin risk-free. Adult safety evidence is limited, and effects around the growth-hormone pathway can include injection reactions, swelling and changes in glucose. The sermorelin side-effects guide covers that narrower question.

Fresh evidence reinforces the cautious answer

As of September 9, 2026, the day this article was written, an August 11, 2026 scoping review of MK-677 and five other performance products found that 67% of the included publications used animal models. Human studies were limited and inconsistent, while documented MK-677 concerns included heart failure and insulin resistance. The authors concluded that current human trials do not substantiate recovery or performance claims (Tewari et al., American Journal of Sports Medicine, 2026).

Supply adds another layer. On June 4, 2026, Australia's drug regulator reported that laboratory testing of capsules labeled as containing 15 mg of ibutamoren found undeclared metandienone, an anabolic steroid (Therapeutic Goods Administration safety alert). That alert involved one product, not every MK-677 seller and not Promise. It shows why a seller's label is not a substitute for a pharmacy record.

The regulatory line is different for each

A December 12, 2025 FDA warning letter says ibutamoren is excluded from the dietary-supplement definition because it was investigated as a new drug first. The letter also says MK-677 products marketed for body effects were unapproved new drugs introduced without an approved application.

No FDA-approved sermorelin product is currently marketed — Geref was approved in 1997 and withdrawn in 2009 — and the compounded formulation offered here is not FDA-approved. FDA later determined that Geref's withdrawal was not for safety or effectiveness reasons (Federal Register, 2013).

FDA status is one clinical fact, not a marketing gate. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed U.S. provider reviews every request and prescribes or declines on medical eligibility. Not everyone qualifies.

What a useful comparison leaves you with

The useful question is not which product sounds easier. It is whether the proposed treatment has evidence for the goal, whether its risks fit the person's history, and who is accountable if something goes wrong. On those terms, gray-market MK-677 and prescribed compounded sermorelin are not equivalent routes.

Getting sermorelin prescribed starts with a compound-specific intake and a real clinical decision. The provider can define what will be monitored, the licensed U.S. compounding pharmacy can identify what it dispensed, and the patient has a clear place to report a reaction.